Health Catalyst, Inc. (NASDAQ:HCAT – Get Free Report) insider Linda Llewelyn sold 1,324 shares of the firm’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $8.16, for a total value of $10,803.84. Following the completion of the transaction, the insider now owns 114,275 shares in the company, valued at $932,484. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Linda Llewelyn also recently made the following trade(s):
- On Monday, September 16th, Linda Llewelyn sold 1,324 shares of Health Catalyst stock. The stock was sold at an average price of $8.43, for a total transaction of $11,161.32.
- On Thursday, August 15th, Linda Llewelyn sold 1,328 shares of Health Catalyst stock. The shares were sold at an average price of $6.57, for a total transaction of $8,724.96.
Health Catalyst Price Performance
Health Catalyst stock opened at $8.66 on Friday. The business has a 50 day moving average of $7.71 and a 200-day moving average of $6.94. The company has a market capitalization of $511.24 million, a P/E ratio of -4.68 and a beta of 1.32. Health Catalyst, Inc. has a 1 year low of $5.42 and a 1 year high of $11.41.
Analyst Upgrades and Downgrades
Several research firms have weighed in on HCAT. Piper Sandler cut their target price on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 26th. Stephens lowered their price target on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a report on Thursday, August 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $16.00 price objective on shares of Health Catalyst in a research note on Friday, October 4th. JPMorgan Chase & Co. boosted their target price on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. Finally, Evercore ISI increased their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $11.58.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of HCAT. Principal Financial Group Inc. increased its stake in shares of Health Catalyst by 6.9% in the second quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock valued at $188,000 after buying an additional 1,907 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in Health Catalyst by 10.3% in the second quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company’s stock valued at $148,000 after acquiring an additional 2,164 shares during the last quarter. Creative Planning increased its position in Health Catalyst by 13.2% during the 3rd quarter. Creative Planning now owns 21,348 shares of the company’s stock valued at $174,000 after purchasing an additional 2,486 shares during the period. Quarry LP raised its holdings in Health Catalyst by 59.4% during the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after purchasing an additional 2,610 shares during the last quarter. Finally, Probity Advisors Inc. raised its holdings in Health Catalyst by 13.3% during the 3rd quarter. Probity Advisors Inc. now owns 23,045 shares of the company’s stock worth $188,000 after purchasing an additional 2,699 shares during the last quarter. 85.00% of the stock is owned by institutional investors.
About Health Catalyst
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.
See Also
- Five stocks we like better than Health Catalyst
- The Significance of Brokerage Rankings in Stock Selection
- Survey Reveals: America’s Most Coveted Businesses in 2024
- 3 Best Fintech Stocks for a Portfolio Boost
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- How to Choose Top Rated Stocks
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.